ADTX Overview

Aditxt, Inc. is a social innovation platform accelerating promising health innovations. The Company operates four programs focused on autoimmunity, cancer and early disease detection, infectious diseases and women’s health. Its subsidiaries include Adimune, Inc. (Adimune), Pearsanta, Inc., Adivir, Inc. and Adifem, Inc. Adimune is focused on its immune modulation therapeutic programs. Adimune’s proprietary immune modulation product, Apoptotic DNA Immunotherapy (ADI), utilizes a novel approach that mimics the way its bodies naturally induce tolerance to our own tissues. Adivir, Inc. is focused on building a portfolio of antiviral and other antimicrobial solutions designed to target life-threatening viral infections and emerging pathogens. Pearsanta, Inc. is engaged in the development of molecular tests based on mitochondrial DNA to develop tests for early detection of cancer. It is also focused on addressing a critical challenge in cancer care: optimizing therapy selection.

Wall Street analysts forecast ADTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aditxt Inc revenue for the last quarter amounts to 12.16K USD, increased 1094.40

Aditxt Inc. EPS for the last quarter amounts to -21343.74 USD, decreased -89.22

Aditxt Inc (ADTX) has 26 emplpoyees as of May 30 2026.

Today ADTX has the market capitalization of 50.92K USD.